BIFIDO. Co. Ltd
KKRX:2382002,405.00
KRW
-155.00
(-6.05%)
ISIN
KR7238200000
Return %
Stock
S&P 500
1Y
-34.82
14.39
3Y
-52.38
81.42
5Y
-79.27
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 102
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Hongcheon-gun South Korea
- IPO Date
- Dec 26, 2018
- Website
- bifido.com
- Similar Companies
- Business
- BIFIDO Co., Ltd. is a South Korea-based biotechnology company primarily engaged in the research, development, manufacturing, and distribution of probiotics, microbiome-derived health functional foods, functional cosmetics, and pharmabiotics. Founded in 1999 and headquartered in Hongcheon-gun, Gangwon-do, South Korea, the company operates as an affiliate of industrial biotechnology specialist Amicogen, Inc. BIFIDO Co., Ltd. organizes its operations into core commercial divisions: Health Functional Foods, Probiotics Raw Materials and OEM/ODM Services, and Microbiome Therapeutics. The company's product and service portfolio comprises proprietary bifidobacteria and lactic acid bacteria raw material strains, including Bifidobacterium bifidum BGN4, Bifidobacterium longum BORI, and Bifidobacterium lactis AD011; finished consumer health supplements marketed under the flagship ZIGUNUK BIFIDUS brand family, such as ZIGUNUK BIFIDUS Premium, ZIGUNUK BIFIDUS Baby, ZIGUNUK BIFIDUS D-Drop, and Bifido Plus for gastrointestinal and immune system health; microbiome-based cosmeceutical skincare solutions under the ViBiome and BIFIDO Lab brands; companion animal probiotics and feed additives; and contract development and manufacturing (CDMO/OEM/ODM) services covering strain cultivation, stabilization, formulation, and custom packaging. Additionally, the company advances a clinical pipeline of live biotherapeutic products (LBPs) focused on immune-modulating indications, including rheumatoid arthritis, atopic dermatitis, and inflammatory bowel diseases. Geographically, BIFIDO Co., Ltd. serves institutional and retail clients across South Korea and exports products and raw materials to international markets across the Asia-Pacific region, North America, and Europe. In recent developments, the company has expanded the global commercialization of its flagship strains backed by U.S. FDA Generally Recognized as Safe (GRAS) notifications and New Dietary Ingredient (NDI) listings; broadened joint manufacturing and supply-chain synergies with parent company Amicogen; launched specialized synbiotic and personalized microbiome functional product lines; and established expanded distribution and supply agreements in international markets, including Greater China and Southeast Asia.